FORME CRISTALLINE DU MONOPHOSPHATE DE N-[6-(FORME CIS-2,6-DIMÉTHYLMORPHOLINE-GROUPE-4)PYRIDINE-GROUPE-3]-2-MÉTHYL-4'-(TRIFLUOROMÉTHOXY)[1,1'-BIPHÉNYL]-3-FORMAMIDE ET SON PROCÉDÉ DE PRÉPARATION
The present disclosure relates to novel crystalline forms of N-[6-(cis -2,6-dimethylmorpholine-4-yl)pyridine-3-yl]-2-methyl)-4'-(trifluoromethoxy) [1,1'-biphenyl]-3-carboxamide monophosphate, and process of preparation thereof. The crystalline form of the monophosphate of a compound of formula (I) has low hygroscopicity, is convenient to store, has better stability than that of diphosphonate in prior art, can avoid the risk of crystal transformation in the development and production of the drug. The preparation method is simple, has low cost, and has important value for further optimization and development of the drug.